The understanding haematological malignancies at the protein level is important for the prediction of therapy response, the possibility for disease diagnostics, the development of targeted treatment, and it must be based on the knowledge regarding the molecular pathogenesis of the tumour. ‘Proteomics’ describes the analysis of the entire proteome of a cell or a tissue and incorporates multiple technologies, including - Western blotting, two-dimensional polyacrylamide gel electrophoresis, mass spectrometry, and ProteinChip-based technology. Although there is a limited number of studies to date in haematological malignancies, those performed highlight the potential impact of these technologies in the discovery of novel markers associated with the drug resistance and the identification of biomarkers which may facilitate the development of a rapid diagnostic test that would be easily applicable in the clinical setting. Thereby this article describes used proteomics techniques and highlights studies regarding proteomic research in haematological malignancies, namely the primarily publications concerning research of multiple myeloma, leukaemias and lymphomas.

        Key words: proteomics, methods, haematological malignancies.